Exercise May Lower Fracture Risk With Rosiglitazone

Exercise May Lower Fracture Risk With Rosiglitazone
Exercise May Lower Fracture Risk With Rosiglitazone

Research in the journal Endocrinology indicates that exercise may partially reduce the risk of increased marrow adipose tissue associated with both diabetes and peroxisome proliferator-activated receptor agonists (PPARs) medications for the treatment of type 2 diabetes.

Maya Styner, MD, assistant professor of medicine at the University of North Carolina School of Medicine in Chapel Hill, and colleagues designed a study in which female mice were assigned to a group with 20mg/kg per day of rosiglitazone or a control group; exercise groups ran 12km per day on running wheels. Femoral MAT volume and tibial bone morphology were evaluated by microcomputer tomography after six weeks.

RELATED: Prevalence of Diabetes, Prediabetes in U.S. Adults: New Report

Mice receiving rosiglitazone therapy had a 40% higher femur MAT volume compared to the control group. Exercise suppressed MAT volume by half in the control mice who exercised vs. control mice who did not and 19% in the rosiglitazone-exercise arm compared with rosiglitazone alone. "Our field is just beginning to investigate bone fat and its implications for patients," Styner said in a statement. She also noted that more marrow adipose tissue means less actual bone, which increases the risk of bone fractures. Clinicians and patients should be aware of this risk and mitigate contributing factors, she concluded.

For more information visit UNC.edu.

Loading links....